The University of Texas MD Anderson Cancer Center is a free-standing comprehensive cancer center within the University of Texas system. In 2011, the institution marked its 70th anniversary and it welcomed Ronald DePinho, M.D., as its fourth full-time president and PI of the CCSG. The mission of MD Anderson is to eliminate cancer in Texas, the nation and the world through outstanding integrated programs of patient care, research, education and prevention. MD Anderson is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. During the last 5 years, the number of cancer center members has increased 14%, facilities including those under construction have increased 56% and new patients have increased to 34,000 annually. Annual citations in Web of Science have increased to 2507 in 2011 (16.5%), including 283 articles in journals with an impact factor >10, reflecting substantial contributions to cancer research. The total research budget increased 40% from $445 million to $624 million. NCI grant support has increased from $115M to $120M (3%) with the largest number of NCI grants for any center (>220), including 11 SPOREs and 13 P01s. Research Programs remain at 19 and support is requested for 16 shared resources. Since the last CCSG renewal, basic science has been strengthened substantially with recruitment of world class leaders in immunology, genomics, proteomics, drug discovery and cancer biology. Translational research has been enhanced and strategic planning implemented to accelerate reductions in cancer deaths in this decade, through MD Anderson's 'moon shot'efforts across the cancer care continuum focused on several major cancers. These planning efforts were made possible by the CCSG disease programs and their well-established multi-disciplinary interactions. Since the last renewal 21 new agents developed at MD Anderson have entered clinical trials, 8 additional agents are expected to enter clinical trials in the next year and 12 INDs were prepared by the cancer center. Clinical research has been strengthened with new leadership, further development of infrastructure and data bases, and emphasis on hypothesis driven, investigator initiated trials. Cancer is a global problem, and MD Anderson has built a network of 26 Sister Institutions in 19 countries to facilitate research and educational activities. Cancer prevention and survivorship is a priority for MD Anderson with an emphasis on molecular epidemiology, behavioral science, clinical cancer prevention and early detection research to reduce the burden of cancer within Texas and worldwide.

Public Health Relevance

Support is requested for 16 shared resources that have facilitated and enhanced research productivity. Funds are also requested for Planning and Evaluation, Senior Leaders, Program Leaders and for Development to enhance faculty recruitment, to provide seed support for multi-investigator grants and to develop a limited number of new shared resources. This support will be critical for MD Anderson's efforts to Make Cancer History.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8731180
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-09-04
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$10,086,149
Indirect Cost
$3,784,951
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Torres, Harrys A; Hosry, Jeff; Mahale, Parag et al. (2018) Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. Hepatology 67:36-47
Parra, Edwin R; Villalobos, Pamela; Behrens, Carmen et al. (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6:48
Yin, Guosheng; Chen, Nan; Lee, J Jack (2018) Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint. Stat Biosci 10:420-438
Nong, Jingying; Gong, Yuhua; Guan, Yanfang et al. (2018) Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun 9:3114
Brown, Justin C; Rickels, Michael R; Troxel, Andrea B et al. (2018) Dose-response effects of exercise on insulin among colon cancer survivors. Endocr Relat Cancer 25:11-19
Vakil, Erik; Jimenez, Carlos A; Faiz, Saadia A (2018) Pleural effusions in hematologic malignancies and their management with indwelling pleural catheters. Curr Opin Pulm Med 24:384-391
Yedururi, Sireesha; Chawla, Sumedha; Amini, Behrang et al. (2018) Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging. Eur J Radiol 105:49-55
Farinholt, Paige; Park, Minjeong; Guo, Ying et al. (2018) A Comparison of the Accuracy of Clinician Prediction of Survival Versus the Palliative Prognostic Index. J Pain Symptom Manage 55:792-797
Oh, Sang Cheul; Sohn, Bo Hwa; Cheong, Jae-Ho et al. (2018) Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun 9:1777
Yang, Yi; Li, Chia-Wei; Chan, Li-Chuan et al. (2018) Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res 28:862-864

Showing the most recent 10 out of 12418 publications